Announced
Financials
Tags
Majority
Domestic
Single Bidder
Pending
Acquisition
Friendly
antibody discovery
Private
United States
Biotechnology
Synopsis
Twist Bioscience, synthetic biology and genomics company, agreed to acquire Abveris, an antibody discovery services company, for $190m. “The addition of the Abveris discovery platform is a natural fit with Twist as it will complement and extend our biopharma antibody capabilities into mouse-based discovery and screening. There are three key approaches to antibody discovery: synthetic libraries, which is the specialty of Twist; in vivo discovery through animal models; and artificial intelligence models. With the anticipated acquisition of Abveris, Twist will have expertise in each, creating a robust antibody design, discovery and screening organization to serve both our partners and our internal pipeline,” Emily M. Leproust, Twist Bioscience CEO and Co-Founder.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.